Avalo Therapeutics Merges with LumiraDx, Renamed LumiraDx
Ticker: AVTX · Form: 8-K · Filed: Jul 30, 2024 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Jul 30, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $2,500,000, $112.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: merger, acquisition, name-change
TL;DR
AVLO is now LMDX after merging with LumiraDx.
AI Summary
On July 29, 2024, Avalo Therapeutics, Inc. announced the closing of its previously disclosed merger with LumiraDx Limited. The merger was approved by Avalo's stockholders on July 26, 2024. Following the merger, Avalo Therapeutics, Inc. will be renamed LumiraDx Limited and will trade under the ticker symbol LMDX.
Why It Matters
This merger signifies a significant change in Avalo Therapeutics' corporate structure and business focus, potentially impacting its stock value and future operations under the new entity.
Risk Assessment
Risk Level: medium — Mergers can introduce integration challenges and market uncertainty, impacting the combined entity's performance.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- LumiraDx Limited (company) — Merging entity
- July 29, 2024 (date) — Merger closing date
- July 26, 2024 (date) — Stockholder approval date
- LMDX (ticker) — New ticker symbol
FAQ
What was the primary event reported in this 8-K filing?
The primary event reported is the closing of the merger between Avalo Therapeutics, Inc. and LumiraDx Limited.
When did the merger officially close?
The merger officially closed on July 29, 2024.
When did Avalo's stockholders approve the merger?
Avalo's stockholders approved the merger on July 26, 2024.
What will be the new name of the company after the merger?
The company will be renamed LumiraDx Limited.
What is the new ticker symbol for the combined company?
The new ticker symbol will be LMDX.
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 13.5 · Accepted 2024-07-30 16:01:41
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market
- $2,500,000 — ule 5550(b)(1) to maintain a minimum of $2,500,000 in stockholders' equity for continued l
- $112.5 million — ported stockholders' equity of negative $112.5 million in its Form 10-Q for the period ended M
Filing Documents
- avtx-20240729.htm (8-K) — 24KB
- 0001628280-24-033437.txt ( ) — 141KB
- avtx-20240729.xsd (EX-101.SCH) — 2KB
- avtx-20240729_lab.xml (EX-101.LAB) — 21KB
- avtx-20240729_pre.xml (EX-101.PRE) — 12KB
- avtx-20240729_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. As previously disclosed, on May 20, 2024, Avalo Therapeutics, Inc. (the "Company") received a notice (the "Notice") from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2,500,000 in stockholders' equity for continued listing on the Nasdaq Capital Market (the "Stockholders' Equity Requirement") because the Company reported stockholders' equity of negative $112.5 million in its Form 10-Q for the period ended March 31, 2024, and, as of the date of the Notice, the Company did not meet the alternatives of market value of listed securities or net income from continuing operations (together with the Stockholders' Equity Requirement, the "Listing Rule") . In accordance with the Nasdaq Listing Rules, the Company submitted a plan of compliance to the Staff. On July 29, 2024, the Company received written notice from Nasdaq that the Staff had granted the Company a 180-day extension, or until November 18, 2024, to exhibit compliance with the Listing Rule. There can be no assurance that the Company will be able to regain compliance with the Listing Rule prior to November 18, 2024. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: July 30, 2024 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 2